Molecular Response After Obinutuzumab Plus High-Dose Cytarabine Induction for Transplant-Eligible Patients With Untreated Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Molecular Response After Obinutuzumab Plus High-Dose Cytarabine Induction for Transplant-Eligible Patients With Untreated Mantle Cell Lymphoma (LyMa-101): A Phase 2 Trial of the LYSA Group
Lancet Haematol 2020 Sep 21;[EPub Ahead of Print], S Le Gouill, A Beldi-Ferchiou, M Alcantara, V Cacheux, V Safar, B Burroni, S Guidez, T Gastinne, D Canioni, C Thieblemont, H Maisonneuve, C Bodet-Milin, R Houot, L Oberic, K Bouabdallah, C Bescond, G Damaj, A Jaccard, N Daguindau, A Moreau, H Tilly, V Ribrag, MH Delfau-Larue, O Hermine, E MacintyreFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.